Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients

Leuk Lymphoma. 2016;57(1):125-8. doi: 10.3109/10428194.2015.1046867. Epub 2015 Sep 23.

Abstract

We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 10(9)/L) during their treatment-course. The majority of the patients experienced marked clinical improvement. Serious side effects were only recorded in a single patient. It is concluded that JAK-inhibition with ruxolitinib is manageable in patients with low platelet counts and should be considered in symptomatic patients who otherwise might not be candidates for treatment.

Keywords: Bleeding; JAK2V617F; myelofibrosis; ruxolitinib; thrombocytopenia.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Blood Platelets
  • Denmark
  • Disease Management
  • Female
  • Humans
  • Janus Kinases / antagonists & inhibitors
  • Male
  • Middle Aged
  • Mutation
  • Nitriles
  • Platelet Count
  • Primary Myelofibrosis / diagnosis
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • Severity of Illness Index
  • Thrombocytopenia / diagnosis
  • Thrombocytopenia / drug therapy*
  • Thrombocytopenia / metabolism
  • Treatment Outcome

Substances

  • Nitriles
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Janus Kinases